




SPACS 2015

Eastgate Biotech CORP  
Rank 16 of 18





SPACS 2015

Eastgate Biotech CORP  
Rank 16 of 18

The relative strengths and weaknesses of Eastgate Biotech CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eastgate Biotech CORP compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 1.6% points. The greatest weakness of Eastgate Biotech CORP is the variable Assets, reducing the Economic Capital Ratio by 250% points.

The company's Economic Capital Ratio, given in the ranking table, is 106%, being 342% points below the market average of 448%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	340	Assets	483
Assets, Non-Current	0	Liabilities	1,881
General And Administrative Expense	3,725	Expenses	4,819
Liabilities, Current	1,881	Revenues	0
Liabilities, Non-Current	0	Stockholders Equity	-1,398
Other Assets	143	Net Income	-4,908
Other Compr. Net Income	15	Comprehensive Net Income	-4,893
Other Expenses	916	BaseVar	3,643
Other Liabilities	0	ECR before LimitedLiability	-1,005%
Other Net Income	-89	Economic Capital Ratio	106%
Other Revenues	0		
Professional Fees	178		